Current HIV/AIDS Reports

, Volume 5, Issue 3, pp 140–149

Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era



In the highly active antiretroviral therapy (HAART) era, the incidence of AIDS-defining malignancies (ADMs) has declined significantly. On the other hand, the incidence of other malignancies not known to be associated with immunosuppression (non-ADMs) has not changed and remains significantly higher than in the general population. Some recent controlled studies even suggest that the incidence of selected non-ADMs has increased in the HAART era. These trends warrant a high index of suspicion for malignancies among HIV care providers and a renewed focus on understanding the mechanisms underlying the increased rates. Potential explanations for the higher non-ADM rates include longer survival of patients with HIV on HAART, with only partial immune recovery achieved in most patients; high incidence of human papillomavirus, Epstein-Barr virus, and hepatitis C virus coinfection in patients with HIV infection; and potential oncogenicity of long-term HIV infection or of long-term HAART.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Mocroft A, Brettle R, Kirk O, et al.: Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002, 16:1663–1671.PubMedCrossRefGoogle Scholar
  2. 2.
    Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853–860.PubMedCrossRefGoogle Scholar
  3. 3.
    Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV: Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006, 145:397–406.PubMedGoogle Scholar
  4. 4.
    Palella FJ Jr, Baker RK, Moorman AC, et al.: Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006, 43:27–34.PubMedCrossRefGoogle Scholar
  5. 5.
    International Collaboration on HIV and Cancer: Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000, 92:1823–1830.CrossRefGoogle Scholar
  6. 6.
    Clifford GM, Polesel J, Rickenbach M, et al.: Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005, 97:425–432.PubMedGoogle Scholar
  7. 7.
    Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA: Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 2003, 32:527–533.PubMedCrossRefGoogle Scholar
  8. 8.
    Herida M, Mary-Krause M, Kaphan R, et al.: Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003, 21:3447–3453.PubMedCrossRefGoogle Scholar
  9. 9.
    Frisch M, Biggar RJ, Engels EA, Goedert JJ: Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001, 285:1736–1745.PubMedCrossRefGoogle Scholar
  10. 10.
    Engels EA, Brock MV, Chen J, et al.: Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006, 24:1383–1388.PubMedCrossRefGoogle Scholar
  11. 11.
    Dal Maso L, Tirelli U, Polesel J, Franceschi S: Trends in cancer incidence rates among HIV-infected patients. Clin Infect Dis 2005, 41:124–127.CrossRefGoogle Scholar
  12. 12.
    Vilchez RA, Finch CJ, Jorgensen JL, Butel JS: The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era. Medicine (Baltimore) 2003, 82:77–81.CrossRefGoogle Scholar
  13. 13.
    Grulich AE, Li Y, McDonald A, et al.: Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002, 16:1155–1161.PubMedCrossRefGoogle Scholar
  14. 14.
    Bedimo R, Chen RY, Accortt NA, et al.: Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989–2002. Clin Infect Dis 2004, 39:1380–1384.PubMedCrossRefGoogle Scholar
  15. 15.
    Bower M, Powles T, Nelson M, et al.: HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003, 17:371–375.PubMedCrossRefGoogle Scholar
  16. 16.
    Engels EA, Pfeiffer RM, Goedert JJ, et al.: Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 2006, 20:1645–1654.PubMedCrossRefGoogle Scholar
  17. 17.
    Kirk GD, Merlo C, O’Driscoll P, et al.: HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007, 45:103–110.PubMedCrossRefGoogle Scholar
  18. 18.
    Burgi A, Brodine S, Wegner S, et al.: Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005, 104:1505–1511.PubMedCrossRefGoogle Scholar
  19. 19.
    Hessol NA, Pipkin S, Schwarcz S, et al.: The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007, 165:1143–1153.PubMedCrossRefGoogle Scholar
  20. 20.
    Baillargeon J, Pollock BH, Leach CT, Gao SJ: The association of neoplasms and HIV infection in the correctional setting. Int J STD AIDS 2004, 15:348–351.PubMedCrossRefGoogle Scholar
  21. 21.
    Phelps RM, Smith DK, Heilig CM, et al.: Cancer incidence in women with or at risk for HIV. Int J Cancer 2001, 94:753–757.PubMedCrossRefGoogle Scholar
  22. 22.
    Serraino D, Boschini A, Carrieri P, et al.: Cancer risk among men with, or at risk of, HIV infection in southern Europe. AIDS 2000, 14:553–559.PubMedCrossRefGoogle Scholar
  23. 23.
    Bedimo R, Dunlap M, McGinnis KA, Justice AC: Incidence of non-AIDS-defining malignancies in HIV-infected vs non-infected veterans in the HAART era: impact of immunosuppression. Presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 17–20, 2007.Google Scholar
  24. 24.
    Patel P, Novak RM, Tong T: Incidence of non-AIDS-defining malignancies in the HIV Outpatient Study. Presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.Google Scholar
  25. 25.
    Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM: Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370:59–67.PubMedCrossRefGoogle Scholar
  26. 26.
    Hartevelt MM, Bavinck JN, Kootte AM, et al.: Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990, 49:506–509.PubMedCrossRefGoogle Scholar
  27. 27.
    Webb MC, Compton F, Andrews PA, Koffman CG: Skin tumours posttransplantation: a retrospective analysis of 28 years’ experience at a single centre. Transplant Proc 1997, 29:828–830.PubMedCrossRefGoogle Scholar
  28. 28.
    Furber AS, Maheswaran R, Newell JN, Carroll C: Is smoking tobacco an independent risk factor for HIV infection and progression to AIDS? Sex Transm Infect 2007, 83:41–46.PubMedCrossRefGoogle Scholar
  29. 29.
    Crothers K, Butt AA, Gibert CL, et al.: Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 2006, 130:1326–1333.PubMedCrossRefGoogle Scholar
  30. 30.
    Bower M, Powles T, Newsom-Davis T, et al.: HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 2004, 37:1563–1565.PubMedCrossRefGoogle Scholar
  31. 31.
    Fox P, Stebbing J, Portsmouth S, et al.: Lack of response of anal intra-epithelial neoplasia to highly active antiretroviral therapy. AIDS 2003, 17:279–280.PubMedCrossRefGoogle Scholar
  32. 32.
    Antoniou T, Tseng AL: Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 2005, 44:111–145.PubMedCrossRefGoogle Scholar
  33. 33.
    Sridhar KS, Flores MR, Raub WA Jr, Saldana M: Lung cancer in patients with human immunodeficiency virus infection compared with historic control subjects. Chest 1992, 102:1704–1708.PubMedCrossRefGoogle Scholar
  34. 34.
    Tirelli U, Spina M, Sandri S, et al.: Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors. Cancer 2000, 88:563–569.PubMedCrossRefGoogle Scholar
  35. 35.
    Powles T, Thirwell C, Newsom-Davis T, et al.: Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART? Br J Cancer 2003, 89:457–459.PubMedCrossRefGoogle Scholar
  36. 36.
    Glaser SL, Clarke CA, Gulley ML, et al.: Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988–1998. Cancer 2003, 98:300–309.PubMedCrossRefGoogle Scholar
  37. 37.
    Biggar RJ, Jaffe ES, Goedert JJ, et al.: Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006, 108:3786–3791.PubMedCrossRefGoogle Scholar
  38. 38.
    Gerard L, Galicier L, Boulanger E, et al.: Improved survival in HIV-related Hodgkin’s lymphoma since the introduction of highly active antiretroviral therapy. AIDS 2003, 17: 81–87.PubMedCrossRefGoogle Scholar
  39. 39.
    Ribera JM, Navarro JT, Oriol A, et al.: Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin’s disease. AIDS 2002, 16: 1973–1976.PubMedCrossRefGoogle Scholar
  40. 40.
    Biggar RJ, Engels EA, Ly S, et al.: Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005, 39:293–299.PubMedCrossRefGoogle Scholar
  41. 41.
    Carter MM, Torres SM, Cook DL Jr, et al.: Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells. Environ Mol Mutagen 2007, 48:239–247.PubMedCrossRefGoogle Scholar
  42. 42.
    Pluda JM, Venzon DJ, Tosato G, et al.: Parameters affecting the development of non-Hodgkin’s lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993, 11:1099–1107.PubMedGoogle Scholar
  43. 43.
    Kirk O, Pedersen C, Cozzi-Lepri A, et al.: Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001, 98:3406–3412.PubMedCrossRefGoogle Scholar
  44. 44.
    Besson C, Goubar A, Gabarre J, et al.: Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001, 98:2339–2344.PubMedCrossRefGoogle Scholar
  45. 45.
    Strickler HD, Burk RD, Fazzari M, et al.: Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005, 97:577–586.PubMedGoogle Scholar
  46. 46.
    Clifford GM, Goncalves MA, Franceschi S: Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006, 20:2337–2344.PubMedCrossRefGoogle Scholar
  47. 47.
    Douek DC: Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Rev 2003, 5:172–177.PubMedGoogle Scholar
  48. 48.
    Sousa AE, Carneiro J, Meier-Schellersheim M, et al.: CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002, 169:3400–3406.PubMedGoogle Scholar
  49. 49.
    Schacker TW, Nguyen PL, Martinez E, et al.: Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. J Infect Dis 2002, 186:1092–1097.PubMedCrossRefGoogle Scholar
  50. 50.
    Ahdieh L, Munoz A, Vlahov D, et al.: Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and-seronegative women. Am J Epidemiol 2000, 151:1148–1157.PubMedGoogle Scholar
  51. 51.
    Palefsky JM, Holly EA, Ralston ML, et al.: Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 2001, 183:383–391.PubMedCrossRefGoogle Scholar
  52. 52.
    McGinnis KA, Fultz SL, Skanderson M, et al.: Hepatocellular carcinoma and non-Hodgkin’s lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol 2006, 24:5005–5009.PubMedCrossRefGoogle Scholar
  53. 53.
    Cheng YW, Chiou HL, Sheu GT, et al.: The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 2001, 61:2799–2803.PubMedGoogle Scholar
  54. 54.
    Nyagol J, Leucci E, Onnis A, et al.: The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesis. Cancer Biol Ther 2006, 5:684–690.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.VA North Texas Health Care System and University of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations